Refine
Has Fulltext
- yes (6)
Is part of the Bibliography
- yes (6)
Document Type
- Journal article (6)
Language
- English (6)
Keywords
- ischemic stroke (2)
- B cells (1)
- C1-inhibitor (1)
- ERK1/2 (1)
- NADPH oxidase inhibitors (1)
- RKIP (1)
- blood coagulation (1)
- blood-brain barrier (1)
- cerebral inflammation (1)
- chronic kidney disease (1)
- colony-stimulating factor (1)
- contact-kinin system (1)
- darbepoetin alpha (1)
- dendric cells (1)
- diabetes mellitus (1)
- dimethyl fumarate (1)
- edema (1)
- experimental stroke (1)
- factor XII (1)
- focal cerebral ischemia (1)
- inflammation (1)
- mice (1)
- neuroinflammation (1)
- oxidative stress (1)
- search filter (1)
- tMCAO (1)
- thrombosis (1)
- transient middle cerebral artery occlusion (1)
- transient middle cerebral artery occlusion model (1)
- translational stroke research (1)
- traumatic brain injury (1)
Institute
EU-Project number / Contract (GA) number
- 294683 (1)
Biomedical research suffers from a dramatically poor translational success. For example, in ischemic stroke, a condition with a high medical need, over a thousand experimental drug targets were unsuccessful. Here, we adopt methods from clinical research for a late-stage pre-clinical meta-analysis (MA) and randomized confirmatory trial (pRCT) approach. A profound body of literature suggests NOX\(_{2}\) to be a major therapeutic target in stroke. Systematic review and MA of all available NOX\(_{2}\)\(^{-/y}\) studies revealed a positive publication bias and lack of statistical power to detect a relevant reduction in infarct size. A fully powered multi-center pRCT rejects NOX\(_{2}\) as a target to improve neurofunctional outcomes or achieve a translationally relevant infarct size reduction. Thus stringent statistical thresholds, reporting negative data and a MA-pRCT approach can ensure biomedical data validity and overcome risks of bias.